Atlas Global Brands signs definitive agreement to acquire control of three Pharmacies in Israel licensed to sell cannabis productsThe medical cannabis pharmacies are located in three new cities,...
The last few months, for all its economic upheaval, have been kind to biomedical venture firms.
NOXXON Pharma N.V. (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it has issued the third and fourth tranche of Convertible Bonds under the financing agreement published on April 23, 2020.
Long before Alexion kindled a renaissance of complement therapeutics with the introduction of the first anti-C5 antibody, Mike Holers — a longtime professor at the University of Colorado School of Medicine — became fascinated with the host defense system as he completed his rheumatology training. As Soliris begins to fade and follow-on, rivals and even generics catch up to the standard bearer. Holers is debuting a next-generation approach he’s been refining with Atlas Venture over the last two years.
Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has entered into a partnership with The Human Protein Atlas (HPA). HPA has selected Horizon’s CRISPR-edited knockout cell models to further expand the knowledge available in its Cell Atlas program, to advance our understanding of the genetic drivers of disease. Knockout cell models offer the possibility for an enhanced validation of antibodies based on genetic strategies, because the complete absence of the targeting protein correlates with a complete loss of signal for specific antibodies. Adding more validation data for the HPA’s antibodies will increase the reliability of the Cell Atlas and thereby help users find the most-trustworthy tools for their research.
The IPO would give Avrobio the means to trial gene therapies designed to supplant enzyme replacement therapies from Sanofi, Shire and Pfizer.
Eisai spinoff H3 Biomedicine has published an analysis of data from The Cancer Genome Atlas (TCGA) showing that genetic mutations in RNA splicing factors are much more common and appear in more cancers than previously thought. The findings open up new indications for H3, which has a clinical-stage candidate for blood cancers and highlights RNA splicing factors as a target for others developing cancer treatments.
Atlas-incubated Kymera Therapeutics has gotten off a $30 million series A and taken on Pierre Fabre’s R&D head as its new chief.
US FDA Issues Form 483 to Atlas Pharmaceuticals, LLC
FDA Form 483 For Atlas Pharmaceuticals